Business Context and Reporting Period
This Form 8-K is filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on May 12, 2020. The filing serves to announce the company's financial results for the quarter ended March 31, 2020. The registrant is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Select Market under the symbol CRTX.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that a business update and financial results for the first quarter of 2020 were announced.
Guidance, Outlook, and Risks
The filing references a press release titled "Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update." However, the specific content regarding guidance, outlook, management commentary, risks, contingencies, or unusual items is not present in the provided text. The information in Item 2.02 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated May 12, 2020), as they are absent from the 8-K body text.
- Confirm the company name is Cortexyme, Inc., noting the discrepancy with the "Quince Therapeutics" label in the request metadata.
- Review the "Business Update" section of the press release for details on clinical trial progress or operational milestones, which are implied but not detailed here.
- Check the company's status as an emerging growth company for potential differences in financial reporting standards.